Karyopharm Therapeutics Future Growth

Future criteria checks 2/6

Karyopharm Therapeutics is forecast to grow earnings and revenue by 34.6% and 21.3% per annum respectively while EPS is expected to grow by 42.9% per annum.

Key information

34.6%

Earnings growth rate

42.9%

EPS growth rate

Biotechs earnings growth	21.3%
Revenue growth rate	21.3%
Future return on equity	n/a
Analyst coverage	Good
Last updated	04 Apr 2024

Recent future growth updates

Recent updates

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 33%

Feb 23

Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)

Feb 05

Improved Revenues Required Before Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock's 27% Jump Looks Justified

Apr 17

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Apr 17

Karyopharm: Market Is Overlooking Growth

Oct 07

Karyopharm Therapeutics Q2 2022 Earnings Preview

Aug 03

Karyopharm cancer therapy eltanexor gets FDA fast track status, orphan drug tag in EU

Jul 20

Karyopharm: Another 2 Year Wait For Data

May 05

Karyopharm: Opportunity To Buy Based On Latest Endometrial Cancer Data And Xpovio Sales Estimates

Feb 19

Karyopharm Therapeutics: Unjustified Sell-Off Provides An Opportunity To Reload My Position

Dec 04

Karyopharm Therapeutics: After Years Of Waiting I'm Ready To Join The Bulls

Sep 16

Analyst Forecasts Just Became More Bearish On Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Aug 07

Earnings and Revenue Growth Forecasts

NasdaqGS:KPTI - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	231	-109	N/A	N/A	5
12/31/2025	165	-182	N/A	N/A	6
12/31/2024	147	-146	N/A	N/A	6
12/31/2023	146	-143	-93	-93	N/A
9/30/2023	146	-140	-101	-101	N/A
6/30/2023	146	-142	-100	-100	N/A
3/31/2023	148	-158	-109	-109	N/A
12/31/2022	157	-165	-150	-150	N/A
9/30/2022	250	-88	-97	-97	N/A
6/30/2022	251	-104	-99	-93	N/A
3/31/2022	234	-108	-119	-113	N/A
12/31/2021	210	-124	-113	-107	N/A
9/30/2021	119	-206	-169	-163	N/A
6/30/2021	102	-208	-184	-184	N/A
3/31/2021	113	-201	-168	-168	N/A
12/31/2020	108	-196	-160	-160	N/A
9/30/2020	91	-201	-169	-169	N/A
6/30/2020	83	-189	-161	-161	N/A
3/31/2020	59	-186	-169	-169	N/A
12/31/2019	41	-200	-191	-191	N/A
9/30/2019	23	-209	-201	-200	N/A
6/30/2019	10	-216	-203	-202	N/A
3/31/2019	20	-206	-193	-191	N/A
12/31/2018	30	-178	-161	-159	N/A
9/30/2018	32	-159	-118	-116	N/A
6/30/2018	31	-142	-100	-100	N/A
3/31/2018	12	-138	-84	-84	N/A
12/31/2017	2	-129	-74	-74	N/A
9/30/2017	0	-117	N/A	-88	N/A
6/30/2017	0	-112	N/A	-87	N/A
3/31/2017	0	-112	N/A	-86	N/A
12/31/2016	0	-110	N/A	-84	N/A
9/30/2016	0	-112	N/A	-85	N/A
6/30/2016	0	-117	N/A	-90	N/A
3/31/2016	0	-119	N/A	-97	N/A
12/31/2015	0	-118	N/A	-94	N/A
9/30/2015	0	-115	N/A	-86	N/A
6/30/2015	0	-104	N/A	-77	N/A
3/31/2015	0	-88	N/A	-61	N/A
12/31/2014	0	-76	N/A	-51	N/A
9/30/2014	0	-62	N/A	-49	N/A
6/30/2014	0	-52	N/A	-41	N/A
3/31/2014	0	-42	N/A	-36	N/A
12/31/2013	0	-34	N/A	-30	N/A
9/30/2013	0	-26	N/A	-24	N/A
6/30/2013	0	-20	N/A	-19	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: KPTI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KPTI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KPTI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KPTI's revenue (21.3% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: KPTI's revenue (21.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if KPTI's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Karyopharm Therapeutics Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 16%

Price target decreased by 7.7% to US$6.00

Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Year 2024

Karyopharm Therapeutics Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year 2023

Price target decreased by 15% to US$5.50

Karyopharm Therapeutics Inc. Reiterates Revenue Guidance for the Full Year 2023

Recent updates

Karyopharm Therapeutics Inc. Announces Presentations in Endometrial Cancer and Myelofibrosis At the 2024 American Society of Clinical Oncology Annual Meeting

Karyopharm Therapeutics Inc., Annual General Meeting, May 29, 2024

New minor risk - Shareholder dilution

New minor risk - Insider selling

Consensus EPS estimates fall by 16%

Full year 2023 earnings: EPS misses analyst expectations

Price target decreased by 7.7% to US$6.00

Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Year 2024

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 33%

Karyopharm Therapeutics Inc. to Report Q4, 2023 Results on Feb 29, 2024

New major risk - Share price stability

Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)

Karyopharm Therapeutics Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year 2023

Karyopharm Therapeutics Receives Non-Compliance Notice From Nasdaq

Karyopharm Therapeutics Inc. Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi-Naive Myelofib) Patients

Karyopharm Therapeutics Inc. Announces Resignation of Peter K Honig as Member of the Board of Directors

Price target decreased by 15% to US$5.50

Karyopharm Therapeutics Inc. Reiterates Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Karyopharm Therapeutics Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Market cap size

Karyopharm Therapeutics Inc. Appoints Zhen Su to Its Board of Directors

Consensus EPS estimates upgraded to US$1.02 loss

Karyopharm Therapeutics Inc. Announces Earnings Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Karyopharm Therapeutics Inc. to Report Q2, 2023 Results on Aug 02, 2023

Karyopharm Therapeutics Inc. Announces Presentation of Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer

Karyopharm Therapeutics Inc. Initiates Pivotal Phase 3 Clinical Trial (XPORT-MF-034) to Assess Efficacy and Safety of Once-Weekly Selinexor 60Mg in Combination with Ruxolitinib in JAKi-Naïve Patients with Myelofibrosis

Consensus EPS estimates upgraded to US$1.28 loss, revenue downgraded

Price target decreased by 12% to US$7.60

Karyopharm Therapeutics Inc. Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Improved Revenues Required Before Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock's 27% Jump Looks Justified

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Surges 27% Yet Its Low P/S Is No Reason For Excitement

President recently sold US$100k worth of stock

Karyopharm Therapeutics Inc. Provides Revenue Guidance for the Full Year 2023

Full year 2022 earnings: EPS misses analyst expectations

Karyopharm Therapeutics Inc. to Report Q4, 2022 Results on Feb 15, 2023

Price target decreased to US$8.89

Karyopharm Therapeutics Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Karyopharm Therapeutics Inc. Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at ASH 2022

Karyopharm Therapeutics Inc. announced that it expects to receive $165.000003 million in funding from a group of investors

High number of new directors

Third quarter 2022 earnings released: US$0.45 loss per share (vs US$0.69 loss in 3Q 2021)

Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Fiscal Year 2022

Karyopharm Therapeutics Inc. and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis

Karyopharm Therapeutics Inc. to Report Q3, 2022 Results on Nov 03, 2022

Karyopharm: Market Is Overlooking Growth

Key Executive notifies of intention to sell stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$10.44

Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Year 2022

Karyopharm Therapeutics Q2 2022 Earnings Preview

Karyopharm Therapeutics Inc. to Report Q2, 2022 Results on Aug 04, 2022

Karyopharm Therapeutics Inc. and Menarini Group Receives Full Marketing Authorisation from the European Commission for NEXPOVIO

Karyopharm cancer therapy eltanexor gets FDA fast track status, orphan drug tag in EU

Karyopharm Therapeutics Inc. Receives Health Canada Authorization for XPOVIO® (selinexor)

The European Myeloma Network and Karyopharm Therapeutics Inc. Announce Dosing of First Patient in Collaborative EMN29/XPORT-MM-031 Study

Karyopharm Therapeutics Inc. and Menarini Group Receive Positive Chmp Opinion for Nexpovio® (Selinexor) for the Treatment of Patients with Refractory Multiple Myeloma

President recently sold US$178k worth of stock

Karyopharm: Another 2 Year Wait For Data

Price target decreased to US$12.20

High number of new directors

Price target decreased to US$12.20

Karyopharm Therapeutics Inc., Annual General Meeting, May 19, 2022

Karyopharm Therapeutics Inc Announces Executive Changes

Michael G. Kauffman, M.D., Ph.D. Notifies Karyopharm Therapeutics Inc. of His Resignation from the Board of Directors

Karyopharm Provides U.S. Regulatory Update on Selinexor in Advanced or Recurrent Endometrial Cancer

Co-Founder recently sold US$110k worth of stock